Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Balkan Medical Journal ; 09:09, 2022.
Article in English | MEDLINE | ID: covidwho-2163944

ABSTRACT

Background: The coronavirus disease 2019 vaccine induces both antibody and T-cell immune responses and has been proven to be effective in preventing coronavirus disease 2019, including its severe disease form, in healthy individuals. However, the details of severe acute respiratory syndrome coronavirus-2 immunoglobulin-G antibody responses and severe acute respiratory syndrome coronavirus-2 specific T-cell responses in patients with sarcoidosis are unknown.

2.
Medicine ; 101(48):e32185, 2022.
Article in English | MEDLINE | ID: covidwho-2161259

ABSTRACT

Bacillus Calmette-Guerin vaccine is administered for protection against tuberculosis and may also have beneficial effects against some viral respiratory tract infections. In this study, it was aimed to investigate the relationship between Bacillus Calmette-Guerin vaccination which is confirmed by BCG scar, and the frequency and course of Coronavirus disease 2019 (COVID-19). Among 490 patients, 400 patients who accepted to participate in the study were included. After the consent of patients, age, gender, body mass index, comorbidities, smoking, history, and the progress of COVID-19 of these patients were investigated;the presence and number of Bacillus Calmette-Guerin scars were recorded by a physician. Data from groups with and without COVID-19 history were compared. There was no relation between presence and number of the BCG scar and COVID-19 related hospitalization and intensive care unit admission. When groups with and without COVID-19 history compared, no statistically significant difference was found with the presence and number of Bacillus Calmette-Guerin scars (P > 0,05). No association was found between the presence or number of BCG scars and the frequency and course of COVID-19 in individuals with Bacillus Calmette-Guerin vaccination history confirmed by the presence of Bacillus Calmette-Guerin vaccine scars. Currently, the most important protection against COVID-19 is the COVID-19 vaccine.

3.
Asia Pacific Allergy ; 12(4) (no pagination), 2022.
Article in English | EMBASE | ID: covidwho-2110637

ABSTRACT

Background: CoronaVac, the first coronavirus disease 2019 vaccine administered in our country, was found safe in clinical trials. Objective(s): We aimed to reveal the rate and features of CoronaVac vaccine-associated allergic reactions among vaccinated healthcare workers (HCWs) in real-life. Method(s): This study was planned as a questionnaire-based study. Participants who reported a postvaccination allergic reaction were interviewed on phone and their medical records were also checked for confirmation. Result(s): A total of 2,488 HCWs took part in the study and 4,054 postvaccination complete questionnaire-responses were obtained. Twenty-one HCWs (female: male, 17:4) with a mean age of 40.95 +/- 10.09 stated that they had an allergic reaction after a total of 23 vaccine injections. Accordingly, the reaction rate was 0.56% among all vaccine doses. The most common reactions were systemic skin reactions (2.7%) consisting of generalized pruritus, diffuse pruritic erythema, urticaria, and maculopapular rash. That was followed by local injection site reaction (0.12%). Anaphylaxis was reported in 4 cases (0.09%) with a mean onset time of 12 +/- 6 minutes. One of them had a history of anaphylaxis with 2 drugs, another had venom and food allergy. Three of the subjects had level 2 diagnostic certainty according to the Brighton Collaboration criteria and one had level 3. All anaphylaxis cases were discharged within 24 hours and none of them required intensive care. Conclusion(s): Our study demonstrated that allergic reactions to CoronaVac were rare and mostly mild. Although anaphylaxis was also rare, the importance of early intervention with close follow-up was once again emphasized. isio Provisional Copyright © 2022. Asia Pacific Association of Allergy, Asthma and Clinical Immunology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Pr.

4.
Black Sea Journal of Engineering and Science ; 5(1):42-53, 2022.
Article in Turkish | CAB Abstracts | ID: covidwho-1893693

ABSTRACT

During the COVID-19 pandemic period, measures taken to control the spread of the virus worldwide;caused a decrease in social, economic and commercial activities. This situation inevitably affected the environmental components directly or indirectly. With the implementation of COVID-19 restrictions, it has been observed that air quality has improved significantly, greenhouse gas emissions have decreased, water pollution and noise levels have slowdown, surface and ground water quality has enhanced and traffic density has reduced in different cities of the world. However, despite these positive effects on the environment, the new corona virus epidemic also caused negative effects such as low indoor air quality, increased use of disposable plastics and medical waste such as masks and gloves, and decreased amount of recycling waste. In this study, it is aimed to reveal the positive and negative effects of the COVID-19 pandemic on environment by reviewing the scientific literatures.

5.
Asian Pacific Journal of Tropical Medicine ; 15(4):171-178, 2022.
Article in English | CAB Abstracts | ID: covidwho-1855963

ABSTRACT

Objective: To identify effects of various nationwide vaccination protocols on the evolution of new SARS-CoV-2 infections among adult population and to evaluate the safety of mRNA (BioNTech/ Pfizer) vaccine.

6.
Neurological Sciences and Neurophysiology ; 39(1):40-47, 2022.
Article in English | EMBASE | ID: covidwho-1818461

ABSTRACT

Introduction: Coronavirus disease 2019 (COVID-19) is known to have higher morbidity and mortality rates, parallel to the increased risk factors in the elderly. We aimed to define the risk factors related to mortality and morbidity in older patients hospitalized with COVID-19 disease in this study. Materials and Methods: This retrospective cross-sectional study included patients aged ≥65 years who were hospitalized with a confirmed diagnosis of COVID-19. We analyzed their demographic data, clinical findings, comorbidities, laboratory and radiologic findings, treatment protocols, and outcomes. Results: A total of 58 patients were included in the study. A total of eight (13.8%) patients died during the clinical follow-up and treatment, and 50 (86.2%) patients were discharged. The most common comorbidities among all patients were hypertension (HT) (69%) and diabetes mellitus (39.7%). The most common symptoms include fever (51.7%), cough (44.8%), and dyspnea (43.1%), and the most common neurologic findings were headache (27.6%) and impaired consciousness (27.6%). Intensive care unit admission was significantly higher among patients with comorbidities of HT, cerebrovascular disease, atrial fibrillation (AF), and chronic obstructive pulmonary disease. The rate of death was significantly higher in patients with a history of smoking, cerebrovascular disease, AF, and HT. Although there was a statistically significant positive correlation between the death rate and leukocyte, neutrophil, C-reactive protein, lactate dehydrogenase, D-dimer, interleukin-6, and procalcitonin levels, a negative correlation was observed in lymphocyte levels. Conclusion: Age-related comorbid conditions, especially HT, cerebrovascular disease, and AF, caused increased morbidity and mortality rates in older patients with COVID-19.

7.
Journal of Urological Surgery ; 9(1):57-62, 2022.
Article in English | EMBASE | ID: covidwho-1792137

ABSTRACT

Objective: This study aimed to present the impact of coronavirus disease-2019 pandemic on seeking treatment in patients with erectile dysfunction (ED) and compare the clinical characteristics, demographics, and laboratory analysis of patients with ED during and before the pandemic period. Materials and Methods: The clinical and demographic characteristics and laboratory analysis of patients with ED were compared between the time interval of March 9, 2020, to June 1, 2020, and the previous 3 months from the pandemics. The International Index of Erectile Function-5 questionnaire was used to assess ED and the results from two groups were compared. Results: A 76.4% decreased total number of outpatient clinics and a 70.9% decreased number of patients with ED was observed;however a significant increase was detected in the ratio of patients with ED to the total number of patients during the pandemic period (1.7% vs. 2.1%, p=0.008). The median age of patients was smaller in the pandemic period. Mild ED was significantly higher in the pandemic period and moderate ED was detected higher in the period before the pandemic. Conclusion: The admission rate of patients with ED has increased in the pandemic period. The patients presenting with ED during the pandemic period were younger, with milder ED symptoms.

8.
Turkish Journal of Biochemistry ; 46(SUPPL 2):63, 2021.
Article in English | EMBASE | ID: covidwho-1766807

ABSTRACT

BACKGROUND AND AIM: The COVID-19 pandemic has been devastating the world since its inception. Routine parameters used in the diagnosis and treatment process can be a potential biomarker for the prognosis of this inflammatory disease. In our study, it was aimed to compare some hemogram and biochemical parameters according to the need for intensive care (ICU) of laboratory-confirmed PCR (+) patients and to evaluate their potential role in determining the prognosis of the disease. METHODS: A total of 255 patients, who were diagnosed with COVID-19 by PCR test in Konya Selcuk University Faculty of Medicine hospital between April and December 2020, 62 of whom were in the ICU and 193 of them were treated for COVID-19 in the service, were included in the study. RESULTS: Considering the demographic and clinical findings of the patients, the mean age of the patients entering the ED was higher (64.65 ± 14.14 vs. 54.65 ± 17.43, p<0.001, respectively) and their saturation was lower (83.56±5.45 vs. 93.05±4.27, p<0.001, respectively). Those entering the ICU were mostly men (64.5% vs. 35.5%, p=0.036) and those with comorbidities (85.5% vs. 14.5%, p<0.001). All of them had Thorax CT involvement (n=62, 100%) and 53.2% were ex. WBC, troponin, procalcitonin, ferritin, D-dimer, CRP, LDH, fibrinogen, neutrophil, platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR) and monocyte/lymphocyte ratio (MLR) of patients entering ICU were significantly high, lymphocyte value was low. On the other hand, there was no significant difference between the platelet and monocytes values of the patients who entered the ICU and those who did not (p=0.526 and p=0.123). When the results obtained by adjusting the patients' age, gender and comorbidities were analyzed, it was observed that the procalcitonin value lost its significance (p=0.480, p=0.529, and p=0.758). Similarly, it was observed that troponin, fibrinogen, and MLR lost significance when corrected (p=0.108, p=0.080, and p=0.124). CONCLUSIONS: It has been observed that in addition to the ferritin, D-dimer, CRP, LDH tests that are routinely used together with the PCR test in the diagnosis and follow-up of COVID-19, neutrophils, PLR and NLR can also be helpful, they are significant in those who need ICU, and procalcitonin measurement is not required.

10.
Am J Stem Cells ; 10(5):79-89, 2021.
Article in English | PubMed | ID: covidwho-1661402

ABSTRACT

The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) started in December 2019 and affected the whole world in a short time. The course of the disease depends on the person's immune system, physical properties, health status, etc. as it varies according to its characteristics while it is asymptomatic in some people, it causes fatal processes that start with flu-like symptoms such as cough, fever, respiratory distress in some people and progress to acute respiratory distress syndrome (ARDS), severe pneumonia and multi-organ dysfunction, and the basic mechanism underlying these effects known as a cytokine storm. There is no specific effective antiviral drug or vaccine in treatment yet. Supportive/alternative treatment methods are needed as both the desired effect cannot be achieved and undesirable side effects are seen with the current treatments used in the clinic. Mesenchymal stem cells (MSCs) are frequently preferred recently from basic studies to clinical studies and are effective and safe in immune-mediated inflammatory diseases such as Systemic Lupus Erythematosus, Graft-versus-Host disease. MSCs can secrete many types of cytokines through paracrine secretion or directly interact with immune cells leading to immunomodulation. According to the results of the completed studies;it has been stated that the cytokine storm caused by the overstimulation of the immune system decreases and even damage of the cytokine storm on organs decreases, respiratory distress is relieved and contributes to the healing process by repairing damaged tissues. In this review, clinical trials completed/ongoing on MSCs recommended for treating COVID-19, a global problem, are reviewed and the review is prepared to specify the existence of such a route to clinicians.

12.
Coronavirus Disease: From Molecular to Clinical Perspectives ; : 197-211, 2021.
Article in English | Scopus | ID: covidwho-1296481

ABSTRACT

The process beginning with some cases of pneumonia of unknown etiology in the city of Wuhan in China at the end of 2019 has continued with the agent being defined as a new virus and announced as a pandemic by World Health Organization (WHO). It has been seen to spread by droplet route and direct contact and usually locate to and cause disease condition in the respiratory tract. It may present asymptomatically or cause a clinical presentation ranging from mild upper respiratory tract infection to adult respiratory distress syndrome due to viral pneumonia. The clinical condition it causes has been named coronavirus disease 2019 (COVID-19). The first impressions on the disease have shown that the disease caused by this new type of virus presents with higher rates of mortality and morbidity in the elderly patients with several co-morbidities including cardiovascular conditions, immune suppressive diseases, metabolic, and chronic respiratory tract diseases. In the initial phase of the pandemic, it has been predicted that the presence of an underlying chronic respiratory tract disease may cause serious co-morbidity because the disease involves the respiratory tract particularly. In the forthcoming period, it has been found that cardiovascular and metabolic diseases might cause more severe co-morbidity compared to respiratory tract diseases. Chronic respiratory tract diseases that may lead to serious co-morbidity during the pandemic include chronic obstructive and restrictive respiratory tract diseases, and respiratory sleep disorders. The first and most important recommendation for patients with chronic respiratory tract diseases should be protection and the precautions. Concern on this point is whether the inhaler and systemic steroids used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma are an extra risk factor. While research on this topic continues, it has been recommended that the patients should continue their treatment as always because no data exists suggesting that they increase the risk. Thus, it has been aimed to maintain stabilization of the disease, decrease hospital exposure, and reduce the risk of COVID-19 contamination. Pulmonary rehabilitation should be recommended to these patients in this process. The similarity between the radiological findings of COVID-19 and interstitial pulmonary diseases is of importance in the differential diagnosis. Additionally, the patients with COVID-19 are a candidate to be a patient with interstitial pulmonary disease because fibrosis may occur in the recovery process of the disease. Patients with obstructive sleep apnea syndrome (OSAS) also have several cardiovascular and metabolic disorders. Thus, OSAS is an extra high-risk factor for COVID-19. Furthermore, positive airway pressure (PAP) devices used in its treatment are additional important threats because they spread aerosols. © 2021 Nova Science Publishers, Inc.

13.
Disaster Medicine & Public Health Preparedness ; : 1-4, 2020.
Article in English | MEDLINE | ID: covidwho-1147328

ABSTRACT

OBJECTIVE: Personal protective equipment (PPE) use is frequently construed as inconvenient and disturbing by health care professionals (HCPs). We hypothesized that new-onset symptoms among HCPs may be associated with extended use of PPE and aimed to investigate risk factors related with new-onset symptoms. In addition, the effects of new-onset symptoms on working performance were evaluated. METHODS: In this cross-sectional study, 315 participants filled out a questionnaire that contains 4 main parts: (1) demographics, (2) new-onset symptoms with PPE use, (3) PPE usage hours, and (4) personal opinion about the effect of sensed symptoms on working performance. RESULTS: The mean age was 31.58 +/- 4.6 years, and 50.5% (n = 159) were female. New-onset symptom rate was 66% (n = 208). The most common new-onset symptom was headache (n = 115, 36.5%) followed by breathing difficulty-palpitation (n = 79, 25.1%), and dermatitis (n = 64, 20.3%). Extended use of PPE, smoking, and overweight were independently associated with developing new-onset symptoms. A clear majority of symptomatic participants pointed out the impact on working performance (193/208, 92.7%). CONCLUSION: Hospitals should take the necessary precautions (eg, shorter shifts and more frequent breaks) to prevent symptoms associated with PPE and ensure that HCPs comply with these precautions.

14.
Disaster Medicine & Public Health Preparedness ; : 1-15, 2020.
Article in English | MEDLINE | ID: covidwho-933597

ABSTRACT

OBJECTIVE: Personal protective equipment (PPE) use is frequently construed as inconvenient and disturbing by healthcare professionals (HCPs). We hypothesized that new-onset symptoms among HCPs may be associated with extended use of PPE and aimed to investigate risk factors related with new-onset symptoms. In addition, the effects of new-onset symptoms on working performance were evaluated. METHODS: In this cross-sectional study, 315 participants filled out a questionnaire that contains four main parts: 1) Demographics, 2) New-onset symptoms with PPE use, 3) PPE usage hours, 4) Personal opinion about the effect of sensed symptoms on working performance. RESULTS: The mean age was 31.58 +/- 4.6 years, and 50.5% (n=159) were female. New-onset symptom rate was 66% (n=208). The most common new-onset symptom was headache (n=115, 36.5%) followed by breathing difficulty-palpitation (n=79, 25.1%) and dermatitis (n=64, 20.3%). Extended use of PPE, smoking, and overweight were independently associated with developing new-onset symptoms. A clear majority of symptomatic participants pointed out impact on working performance (193/208, 92.7%). CONCLUSION: Hospitals should take the necessary precautions (e.g. shorter shifts and more often breaks) to prevent symptoms associated with PPE and ensure that HCPs comply with these precautions.

15.
GIDA Journal of Food ; 45(4):646-664, 2020.
Article in Turkish | GIM | ID: covidwho-831233

ABSTRACT

COVID-19 outbreak caused by SARS-CoV-2 virus, has recently been taken hold of worldwide and caused thousands of people death. Although COVID-19 is not a food-borne outbreak, foods can mediate the spread of COVID-19. Thus, prevention of contamination of foods with COVID-19 or inactivation of the virus from contaminated foods could be provided by ensuring good hygiene practices in food establishments, being careful in personnel hygiene, washing fruit and vegetables with plenty of water before processing and consumption, cooking foods at proper temperatures and avoid crosscontamination. Ethanol ( 70%), NaClO (0.1%), Hsub2/subOsub2/sub and quaternary ammonium compounds are suggested as disinfectants to inhibit COVID-19. In this study, information has been reviewed about the spread of COVID-19 through foods, making foods safe in terms of COVID-19, measures to be taken against COVID-19 in food establishments during production, transportation, service and selling stages and disinfectants that can be used in food premises for this purpose.

SELECTION OF CITATIONS
SEARCH DETAIL